However, roughly 30% of patients cannot tolerate this prodrug. MMF is converted by the liver to the active ingredient ...
Takakura Y, Kitajima M, Matsumoto S, Hashida M, Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C- ... Takakura Y, Atsumi R, Hashida M, Sezaki H. Development of a novel polymeric prodrug of mitomycin C, mitomycin C-dextran ...